Monitor for any subsequent validation data or FDA submission announcements that could signal commercial progress. The CHEST presentation is a routine scientific update with no immediate catalyst for the stock.
Price Chart
Executive Summary
bioAffinity Technologies filed an 8-K announcing a poster presentation at CHEST 2026 on its investigational sputum-based tests to measure lung inflammation and detect protein biomarkers for asthma and COPD. The tests are in early development, not FDA-cleared, and not commercially available. This is a routine research update with no financial data or near-term revenue impact.
Key Facts
- Poster presentation at CHEST 2026 (October 20, 2026) titled 'Sputum as a Diagnostic Tool for the Measurement of Lung Inflammation in Asthma'
- Tests are investigational, not validated, not FDA-cleared or approved, and not available for clinical or diagnostic use
- Research measures cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targets (TSLP, CRLF2, IL4-Rα, IL-5)
- Global asthma therapeutics market projected to reach $47.6 billion by 2034 (third-party estimate cited in press release)
- No financial figures, revenue, or material agreements disclosed in the filing
Financial Impact
No financial impact disclosed; tests are pre-commercial and not generating revenue
Risk Factors
- Tests are investigational and may never receive FDA clearance or achieve commercial viability
- No timeline provided for clinical validation or regulatory submission
- Company has no current revenue from these tests; development-stage risk remains high
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-046755 |
| Exhibit: ex99-1.htm | 0001493152-26-046755 |
| Document: 0001493152-26-046755-index-headers.html | 0001493152-26-046755 |
| Document: 0001493152-26-046755-index.html | 0001493152-26-046755 |
| Document: 0001493152-26-046755.txt | 0001493152-26-046755 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEF 14A | $2.81 | awaiting T+1 | — | $2.83 (+0.71%) |
Oct 15, 2026 11d ago | 8-K | $3.96 $3.73 | ▼ −5.81% | ▼ −4.70% | $2.83 (−28.54%) |
Oct 13, 2026 13d ago | 8-K | $3.63 $3.56 | ▼ −1.79% | ▼ −0.71% | $2.83 (−21.93%) |
Oct 9, 2026 17d ago | 8-K | $3.90 $3.63 | ▲ +7.05% | ▲ +7.04% | $2.83 (+27.44%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▲ +17.46% | ▲ +17.40% | $2.83 (+40.11%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▼ −17.46% | ▼ −17.40% | $2.83 (−40.11%) |
Oct 8, 2026 18d ago | 8-K | $5.64 $4.73 | ▼ −16.22% | ▼ −16.82% | $2.83 (−49.82%) |
Oct 6, 2026 20d ago | 8-K | $6.06 $6.16 | ▲ +1.65% | ▲ +1.89% | $2.83 (−53.30%) |
Sep 30, 2026 26d ago | 8-K | $6.56 $6.15 | ▼ −6.33% | ▼ −6.50% | $2.83 (−56.86%) |
Sep 22, 2026 4w ago | 8-K | $8.56 $7.94 | ▼ −7.19% | ▼ −6.47% | $2.83 (−66.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers